This study will look at how enhanced cancer screening using will improve early detection rates and further understanding of how inherited mutations can lead to development of cancer.

This Study is Open To:

Men age 35-74 years old who meet the following criteria may be eligible:

No prior diagnosis of cancer
Meets either group 1 or group 2 criteria:
- Group 1: has an in one of the following genes: , ATR, , , , , , FANCA, GEN1, , , , , , , , , , .
- Group 2: has a strong family history suggestive of high genetic risk for cancer but with no inherited genetic mutation.

This Study is NOT Open To:

Men are not eligible to participate if they:

have had a prior diagnosis or treatment of cancer
are not able to undergo a MRI or receive the contrast agent

What the Study Involves

Two groups of patients will be enrolled in this study:

One group will enroll people who have an in one of the following genes: , ATR, , , , , , FANCA, GEN1, , , , , , , , , ,
The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for cancer.

Both study groups will receive the same cancer screening tests:

physical exam (digital rectal exam)
prostate-specific antigen () test
of the .

Study participants will be followed for up to 20 years.

Study Contact Information:

For additional information, please contact:

Olympia Price by phone: 857-238-3838
or by email: oprice@partners.org

Locations:

Massachusetts

Massachusetts

City: Boston RECRUITING
Facility: Massachusetts General Hospital
Contact Info:
oprice@partners.org 857-238-3838 Olympia Price

Prevention

Study Contact Information:

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Prevention

Study Contact Information:

About the Study

This Study is Open To:

This Study is NOT Open To:

What the Study Involves

Study Contact Information:

Locations:

Massachusetts

Knowledge Can Save Lives